+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
Small-Cell Lung Cancer (SCLC): Market View - Product Thumbnail Image

Small-Cell Lung Cancer (SCLC): Market View

  • Report
  • September 2026
  • 141 Pages
  • Global
From
From
Global Oncology Market Strategic Research Report 2026-2031 - Product Thumbnail Image

Global Oncology Market Strategic Research Report 2026-2031

  • Report
  • August 2026
  • 328 Pages
  • Global
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more